1 / 49

Managing Menstrual Abnormalities

Managing Menstrual Abnormalities. Jan Shepherd, MD, FACOG. Objectives. Identify common causes of menstrual abnormalities and discuss their pathophysiology. Describe office, laboratory, and additional evaluation of menstrual abnormalities.

hija
Télécharger la présentation

Managing Menstrual Abnormalities

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Managing Menstrual Abnormalities Jan Shepherd, MD, FACOG

  2. Objectives • Identify common causes of menstrual abnormalities and discuss their pathophysiology. • Describe office, laboratory, and additional evaluation of menstrual abnormalities. • Identify management options for acute and chronic abnormal uterine bleeding.

  3. The Normal Menstrual Period • Blood loss < 80 cc (average 30-35 cc) • Duration of flow 2-7 days (average 4 days) • Cycle length 21-35 days (average 29 days) • Mid-cycle spotting can occur with ovulation, but other bleeding between periods is abnormal Consider using menstrual calendar to evaluate

  4. Abnormal Uterine Bleeding (AUB) • Any change in menstrual period • Flow (menorrhagia) • Duration • Frequency (polymenorrhea) • Bleeding between cycles (metrorrhagia) • 20 million office visits/year • 25% of visits to women’s health practitioners

  5. Causes of Abnormal Uterine Bleeding • Complications of Pregnancy • Miscarriage/Retained tissue • Ectopic pregnancy • Trophoblastic disease (e.g. molar pregnancy) • Pelvic Pathology • Vaginal/Vulvar • Cervical – infection, polyp, dysplasia/Ca • Uterine – endometrial polyps, hyperplasia/Ca

  6. Uterine Fibroids (Leiomyomata) • Occur in 20-40% of reproductive-aged women • Rule out other causes! • Diagnosis based on physical exam • Ultrasound for • Rule out submucous • Uncertain adnexal status • Worrisome interval growth

  7. Coagulation Disorders • Inherited coagulopathy is the cause of AUB in 18% of Caucasian and 7% of African-American women • Most commonly presents in adolescence • Von Willebrand’s disease is the #1etiology • Occurs in ~1% of Caucasians • Order coagulation screen and Von Willebrand’s factor (ristocetin cofactor assay) or PFA-100 • Consider referral to hematologist

  8. Common Medical Causes of AUB • Endocrinopathies • Thyroid most common • Systemic diseases • Blood dyscrasias (e.g. leukemia, ITP) • Liver or kidney disease • Medications • Hormones, including contraception, HRT, corticosteroids • Psychotropic drugs • Anticoagulants • Herbs and botanicals – esp. soy, ginseng, ginkgo

  9. Dysfunctional Uterine Bleeding (DUB) • No anatomic, systemic or iatrogenic cause • Presumed disruption in normal ovarian function • Usually anovulation (“Anovulatory bleeding”) • Continuous estrogen exposure causes excessive endometrial proliferation; no progesterone to control and stabilize this growth  uncoordinated shedding • DUB usually irregular cycles, heavy, and long duration • Unopposed estrogen can lead to endometrial Ca

  10. The Normal Menstrual Cycle

  11. Common Etiologies for DUB • Perimenarche or perimenopause • Obesity • Stress (emotional or physical) • Other hormone imbalance (esp. PCOS)

  12. Checklist forMaking the Diagnosis in AUB

  13. Important Elements in History of AUB • Onset • Gradual vs. sudden • Perimenarche, perimenopause • Temporal associations (postcoital, postpill, postpartum) • Characteristics • Volume • Duration • Is she ovulating? • Regularity? Variability? • Menstrual cramps? PMS? • History of infertility

  14. Associated Symptoms • Systemic symptoms • Weight gain or loss • Fatigue, N&V • Fever • Symptoms of endocrinopathy • Androgen Excess • Thyroid • Pituitary • Symptoms of coagulopathy

  15. Additional Focused History • Gynecologic history • Pap tests and annual exams • Past pelvic surgeries or problems • Past Medical History • Medical illnesses • Surgeries • Medications • Family History • Menstrual Abnormalities • Coagulopathies • Gynecologic cancers

  16. Checklist for Physical Exam for AUB • Bruising, petechiae • Low or high BMI • Hirsutism or acne (Hyperandrogenism) • Acanthosis nigricans • Enlarged thyroid or thyroid nodule • Galactorrhea • Complete pelvic exam

  17. Checklist for Laboratory Evaluation of AUB • Rule Out Pregnancy • CBC • TSH • Coagulation profile if indicated (esp teenager) • Chem screen if indicated • 17OHP, Testosterone, and DHEAS if indicated

  18. Additional Testing • Endometrial Biopsy (esp if DUB suspected) • > 35 years old • obese, diabetic, hypertensive • PCOS • Findings • Proliferative vs secretory endometrium (is she ovulating?) • Simple or complex hyperplasia +/- atypia, endometrial ca • Chronic endometritis • Atrophic endometrium • Insufficient for diagnosis  needs further testing

  19. Additional Testing • TransvaginalUltrasonography • Measure endometrial stripe (< 5 mm reassuring) • Rule out endometrial pathology, fibroids, ovarian pathology • Saline Installation - Sonohysterography • Useful in further evaluating intracavitary abnormalities • Superior to TVS alone

  20. Saline Installation Sonography

  21. Additional Testing • Hysteroscopy with directed biopsy • Definitive diagnosis • Excision of endometrial polyps, submucous fibroids • MRI • Can further characterize pelvic and intrauterine lesions, e.g. adenomyosis vs fibroids, penetration depth of fibroids

  22. Endometrial Polyps Slide courtesy of Linda Darlene Bradley, MD.

  23. Am Fam Physician 2004;69:1915-26.

  24. Management of AUB

  25. Management of Acute AUB/DUB • Can be a life-threatening emergency • Monitor Vital signs • IV fluids • Type and Crossmatch • Estrogen - 25 mg IV q 4-6 hrs x 24 hrs or 10-20 mg po in 4 divided doses over 24 hrs • 30-35 μg OCP, Norethindrone acetate 5 mg, or Medroxyprogesterone acetate 20 mg tid x 7, tapering to qd x 3-6 weeks

  26. Management of Chronic AUB/DUB • General Health Measures • weight control • stress reduction • iron supplements • NSAIDS (Antiprostaglandins) – blood loss  50-80% • NEW – Tranexamic acid – superior to NSAIDS • Blocks plasminogen/plasmin  prevents breakdown of fibrinogen  preserves fibrin matrix  stabilizes clots • Two 650 mg tabs tid x 5 days per cycle • Contraindicated with thrombophilia and with OCPs

  27. Management of Chronic AUB/DUB • Progestins (control bleeding & prevent endometrial Ca) • Oral contraceptives, if not contraindicated • Cyclic progestins (days 5-26) • Norethindrone acetate • Medroxyprogesterone acetate • Progestin-only contraception • Progestin-only pills • Depo Provera • Levonorgestrel IUC • Endometrial Ablation

  28. LNG IUS vs Endometrial Ablation Recent Meta-analysis  Efficacy of LNG IUS  Endometrial Ablation up to 2 years after treatment Year 1 Year 1 Year 1 YearYear 1 Year 2 Year 3 Obstet Gynecol 2009;113:1104-16.

  29. Global Endometrial Ablation • Indication • Idiopathic menorrhagia (pathology ruled out) in premenopausal woman who has completed childbearing and failed hormonal therapy • Contraindications • Pregnancy or desire for future pregnancy • Premalignant endometrial changes or endometrial carcinoma • History of classical C-section or transmural myomectomy • Uterine anomaly • Untreated PID, hydrosalpinx

  30. Considerations for Endometrial Ablation • Patient expectations • Does she understand she will still need contraception? • Will she be satisfied with reduced flow? • 23% amenorrhea1 • 16% will need further treatment within 5 years1 • 20-40%in other series • Highest failure rate1 • Age < 45 • Parity > 5 1. Obstet Gynecol 2009;113:97-106.

  31. Comparison of Methods Obstet Gynecol 2006;108:990-1003.

  32. Case • A 14-year-old Caucasian female is brought in by her mother because she has been having periods every 2 weeks for the past 3 months. Currently she has been bleeding for 2 days, is filling a pad every 3 hours, and flooding the bed overnight. Periods began at age 13 but were initially 3 months apart and not as heavy. Patient and her mother deny any past medical problems and state she is not sexually active.

  33. Adolescent • Pregnancy test! • Rule out coagulation disorder • Order CBC,coag screen and Von Willebrand’s panel (vWF, ristocetin cofactor, PFA-100, etc.) • OCP or Norethindrone acetate 5 mg tid x 7, tapering to qd x 3 weeks • Consider maintenance OCP

  34. Case • A 36-year-old Caucasian female g2p2 presents c/o bleeding constantly for over a month. The flow has varied but now fills about 5 pads per day. Her periods have been increasingly irregular, heavy, and long for the past few years. PE reveals BMI of 36, bp 140/86, pelvic exam difficult to evaluate but no gross abnormalities noted. Bright red blood seen flowing from cervical os. How will you manage this patient?

  35. Obesity-Related AUB • Pregnancy test! • Estrogen excess  Consider endometrial biopsy • Norethindrone acetate 5 mg tid x 7, tapering to qd x 3 weeks • Consider Mirena IUC • Consider maintenance progestin therapy: medroxyprogesterone acetate 5-10 mg or norethindrone acetate 5 mg cycle days 5-26

  36. Case • A 49-year-old AA woman g2p2 presents c/o almost continuous bleeding for the past month. Her menses have been becoming further apart (LMP 3 months ago), heavier, and longer, but this is the worst so far. She has been having some hot flashes lately but otherwise feels well. She was told in the past that she had uterine fibroids and is currently taking medication for hypertension. Her BMI is 28.

  37. Perimenopausal Woman • Pregnancy test! • Consider endometrial biopsy • Norethindrone acetate 5 mg tid x 7, tapering to qd x 3 weeks • Consider • Maintenance OCP, if not contraindicated • Maintenance progestin therapy • Levonorgestrel IUC

  38. COCPs for Perimenopause • Benefits • Regulation of menses • Symptom relief • Maintenance of bone density • Risks • Safe for nonsmokers with no CV risk factors • Incidence of VTE increases at age 40 • Exercise caution with high risk, esp. obesity

  39. IUCs for Perimenopausal Women • Among perimenopausal women who are bleeding normally or less frequently, either the Copper IUC or the levonorgestrel IUC is acceptable • Among women who are bleeding abnormally • Preinsertion endometrial evaluation is recommended • If no intrauterine pathology, hormone-releasing IUDs may help control bleeding and prevent endometrial hyperplasia

  40. Innovative Management of Fibroids • Medical • GnRH agonists/antagonists • Aromatase inhibitors (anastrozole, letrozole) • Anti-progesterone (mifepristone) • Interventional • Endometrial Ablation • Endoscopic myomectomy • Hysteroscopy • Laparoscopy • Radiologic management • Uterine artery embolization • MRI-guided focused ultrasound (ExAblate)

  41. Amenorrhea/Oligomenorrhea

  42. Definitions • Primary Amenorrhea – no spontaneous uterine bleeding by the age of 16 • Secondary Amenorrhea – absence of menses for 6 months or more • Oligomenorrhea – menstrual cycle > 35 days

  43. Causes of Primary Amenorrhea • Hypothalamic/Pituitary • Constitutional • Systemic Illness • Extreme physical, nutritional, or emotional stress • PCOS • Ovarian • Gonadal dysgenesis (esp Turner’s Syndrome) • Anatomic • Mullerian anamolies or agenesis (e.g. absent vagina) • Imperforate hymen

  44. Causes of Secondary Amenorrhea • Pregnancy or Breast-Feeding • Hypothalamic • Extreme physical, emotional, or nutritional stress • Systemic illness • PCOS • Obesity • Perimenarche, perimenopause • Pituitary • Hyperprolactinemia • Ovarian • Premature ovarian failure • Uterine • Iatrogenic

  45. Evaluation of Amenorrhea/Oligomenorrhea • Rule Out Pregnancy • Complete H and P with focus on Weight, Hirsutism, Galactorrhea • TSH, Prolactin • FSH, LH • Testosterone, DHEAS (if indicated) * Treat based on etiology

More Related